Daily digest — 2026-09-15

"Among the first" matters less than what Lykos's 2024 rejection taught this field: FDA's psychedelic bar is procedural — blinding integrity, therapist-assisted dosing, abuse-liability and REMS design — not just topline efficacy. Definium has now proven the molecule three times over; it hasn't yet proven it solves the trial-design problem that sank MAPS. Compass Pathways is still fighting depression with psilocybin, MindMed trails on Phase 3 timing — Definium's 2/2 in anxiety and 3/3 overall looks like a real platform effect, not a lucky readout, and that replication is the sharper differentiator than filing order. GAD's addressable population dwarfs the PTSD and treatment-resistant-depression pools psychedelics have chased; the market upside here is genuinely bigger than prior programs, but only if in-clinic monitoring costs don't eat the model. Net effect: this de-risks the pharmacology for the whole psychedelic class more than it de-risks Definium's commercial path — REMS and administration burden, not another efficacy win, are now the swing factor for 2027.

Look at the cash waterfall before reading this as a disaster: SK already wired the firm money pre-hold, and Biohaven keeps it no matter what the FDA ultimately decides — the $395M in milestones and royalties was always the risk-bearing tranche, so SK's real downside exposure was deferred by deal structure, not dodged by luck. The sharper question is timing: a partial hold landing nine days after signature invites an obvious diligence question — was the rodent metabolite finding already in Biohaven's IND file when SK signed, or did SK simply outrun its own risk review? Practically, this is noise, not crisis: RISE-3 is fully enrolled, so the pivotal readout timeline is intact; only RISE-2's tail enrollment stalls. The bigger tail risk is reputational spillover to Kv7 as a mechanism class — that would sting Xenon's azetukalner more than it dents Biohaven's balance sheet.

A $57.5M floor bid for a company with an FDA-approved, already-marketed drug is the real tell here — Oaktree's credit agreement, not Igalmi's commercial prospects, forced this outcome. Whether Teva's up-to-$125M offer looks cheap hinges entirely on that November 14 at-home sNDA decision: clear it, and the milestone structure lets Teva capture most of the upside for a fraction of what a clean acquisition would cost; miss it, and Teva still walks away with a marketed asset at a steep discount either way. For Teva, this reads as opportunistic bolt-on shopping in neuroscience/CNS rather than strategic necessity — cherry-picking distressed assets is cheaper than building pipeline. The bigger lesson: an approved drug is necessary but not sufficient — BioXcel burned through cash on commercial launch faster than Igalmi could generate returns, and Section 363 stalking-horse auctions are becoming the default off-ramp for single-asset biotechs that can't bridge to profitability.